Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

作者
Julien Taı̈eb,Yves Rinaldi,Anne‐Laure Pointet,Emilie Barbier,Faïza Khemissa,Alain Gratet,Laurent Miglianico,Hortense Laharie-Mineur,Karine Bouhier‐Leporrier,François Ghiringhelli,Anne Thirot Bidault,Patrick Texereau,Romain Coriat,Eric Terrebonne,Marie-Claude Gouttebel,David Malka,Côme Lepage,Jean‐Baptiste Bachet
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 4107-4107 被引量:11
标识
DOI:10.1200/jco.2018.36.15_suppl.4107
摘要

4107 Background: Chemotherapy is effective in mPDAC but new approaches are still needed to improve patients (pts) survival and quality of life. We have previously published successful results of a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI regimen1 with good efficacy and tolerability results. In the present study, we tested the same sequence with the new gemcitabine + nab-paclitaxel (G+A) first-line standard therapy2. Methods: We randomized chemotherapy-naive pts with proven mPDAC, bilirubin levels ≤1.5 ULN and performance status (PS) 0-2 to receive in alternance G+A (MPACT regimen)2 (2 months [mo]) and FOLFIRI.3 (FIRGEM regimen)1 (2 mo; arm A), or G+A alone (arm B). The primary objective was to increase the 6-mo progression-free survival (PFS) rate from 40% (H0) to 60% (H1; binomial exact method; required 124 pts). Analyses were done in preplanned modified intent-to-treat (mITT, pts who received at least one dose of treatment) and per-protocol (PP, pts reaching the 2 mo treatment switch) populations. Results: Between Nov 2015 and Nov 2016, 127 pts were enrolled. Mean age was 64 years (range: 38-76), PS was 0/1/2 in 37/51/12%, no major imbalance for baseline characteristics was noted between arms. Main grade 3-4 toxicities per pt (%) were (arms A/B): diarrhea (13/2), nausea/vomiting (9/2), neutropenia (42/31), febrile neutropenia (2/0), skin toxicity (5/14), and peripheral neuropathy (13/20). No toxic deaths occurred. Best objective response rates (mITT) were A: 40% (95%CI, 28-54) and B: 25% (95%CI, 15-38). 6-mo PFS rates were A: 45% and B: 23% in mITT (n = 122; HR: 0.70; 95%CI, 0.48-1.03) and A: 60% and B: 30% in PP (n = 90; HR: 0.57; 95%CI, 0.36-0.90). Median OS (PP) was A: 15.8 and B: 12.4 mo (HR: 0.66. 95%CI, 0.37-1.16). Conclusions: The FIRGEMAX strategy with G+A followed by FOLFIRI.3 every 2 mo, appears to be feasible and effective, with manageable toxicities and decreased neurotoxicity, in patients with mPDAC able to reach > 2mo of treatment for their disease. 1-Trouilloud EJC 2014 2-Von Hoff NEJM 2013 Clinical trial information: NCT02827201.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桐桐的应助被挂机了采纳,获得10
刚刚
Gzzz完成签到 ,获得积分10
刚刚
刘小甜发布了新的文献求助10
刚刚
打打的应助被老北京采纳,获得10
刚刚
初景的应助被Rosa采纳,获得20
刚刚
汐总完成签到,获得积分10
1秒前
李文亚发布了新的文献求助10
1秒前
在水一方的应助被sly采纳,获得10
1秒前
栖木完成签到,获得积分10
1秒前
lql完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
LL发布了新的文献求助10
2秒前
给里奥发布了新的文献求助10
2秒前
2秒前
cai发布了新的文献求助10
3秒前
321完成签到,获得积分0
3秒前
希望天下0贩的0的应助被youyyuy采纳,获得10
3秒前
惊叹鸡腿发布了新的文献求助10
3秒前
3秒前
3秒前
激动的白梅完成签到,获得积分10
4秒前
mengdi发布了新的文献求助10
4秒前
羽毛笔完成签到,获得积分10
4秒前
执着小玉完成签到 ,获得积分10
4秒前
BUT发布了新的文献求助10
4秒前
Cheryl发布了新的文献求助50
5秒前
kathy完成签到,获得积分10
5秒前
HH完成签到 ,获得积分10
5秒前
6秒前
6秒前
小福星的应助被江闲采纳,获得10
6秒前
7秒前
健康的宛菡完成签到,获得积分10
7秒前
杨子墨完成签到,获得积分10
7秒前
情怀的应助被冷酷白晴采纳,获得10
7秒前
7秒前
天天快乐的应助被周周采纳,获得10
8秒前
张张完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287